蘑菇视频APP

CAMBRIDGE, Mass., September 26, 2017 鈥� Rubius Therapeutics, a biotechnology company pioneering the creation of a new class of extraordinarily active, ready-to-use and life changing cellular therapies, today announced that it has been named by FierceBiotech as one of 2017鈥檚 Fierce 15 biotechnology companies, recognizing it as one of the most promising private biotechnology companies in the industry.

鈥淲e are honored to be selected as a Fierce15 company,鈥� said Torben Straight Nissen, Ph.D., president of Rubius Therapeutics. 鈥淩ubius is developing an entirely new class of ready-to-use cell therapeutics to treat cancer, enzyme deficiency disorders and autoimmune diseases 鈥� and we are committed to bringing the promise of red cell therapeutics to patients as soon as possible.鈥�

The Fierce 15 celebrates the spirit of being 鈥渇ierce鈥� 鈥� championing innovation and creativity, even in the face of intense competition. This is 贵颈别谤肠别叠颈辞迟别肠丑鈥檚 fifteenth annual Fierce 15 selection. An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day鈥檚 top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About FierceBiotech

FierceBiotech is the biotech industry鈥檚 daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 160,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day鈥檚 top stories. Signup is free at .

About Rubius Therapeutics

Rubius Therapeutics, a 2017 鈥淔ierce 15鈥� award winner, is creating Red-Cell Therapeutics鈩� (RCTs鈩�) as a new class of medicines to address a wide array of indications. Leading applications include programs in cancer, rare and autoimmune disease, as well as additional potential in infectious and metabolic diseases. The company was conceived and launched by Flagship VentureLabs^庐, the institutional innovation foundry where a team of scientific entrepreneurs systematically evolves enterprising ideas into new fields, or previously undiscovered areas of science into real-world inventions and ventures. The company was founded by 蘑菇视频APP in 2014 and has been capitalized with $140 million to date. For more information please visit us at www.rubiustx.com.

About Red-Cell Therapeutics鈩�

Red-Cell Therapeutics鈩� are genetically engineered, enucleated red cells that are being developed to provide allogeneic, off-the-shelf therapies to patients across multiple therapeutic areas. RCT advantages over other therapies include immuno-privileged presentation of proteins within or on the red cell, high target avidity and affinity resulting in highly potent and selective therapies, and long circulation half-life. Rubius RCTs exhibit fundamentally unique biology and have been engineered to replace missing enzymes for patients living with a variety of rare diseases, to kill tumors, and upregulate or downregulate the immune system to treat both cancer and autoimmune disorders.